Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Biopharmaceutical Industry Capability Building in India: Report from a Symposium.

Journal of pharmaceutical innovation·2021

Same author

Building trust in the quality of vaccines.

Human vaccines & immunotherapeutics·2021

Same author

Recommendations for Enhancing Quality and Capability of Indian Biopharmaceutical Industry: Summary of a Workshop.

Journal of pharmaceutical sciences·2020

Same author

NIST Interlaboratory Study on Glycosylation Analysis of Monoclonal Antibodies: Comparison of Results from Diverse Analytical Methods.

Molecular & cellular proteomics : MCP·2019

Same author

Improvements in corticosteroid 21-acetoxy-17α-hydroxy-16α-methyl-pregna-1,4,9(11)-triene-3,20-dione synthesis and its use as common intermediate in the synthesis of some impurities related to dexamethasone and mometasone.

Steroids·2019

Same author

Novel pyrazole-3-carboxamide derivatives as cannabinoid-1 (CB1) antagonists: journey from non-polar to polar amides.

Bioorganic & medicinal chemistry letters·2010

Search research articles

Related Experiment Videos

Advances in antithrombotic agents.

Ranjan Chakrabarti¹, Saibal Kumar Das

¹Discovery Biology, Dr Reddy's Laboratories Limited, Discovery Research, Bollaram Road, Miyapur, Hyderabad-500 049, India. ranjanchakrabarti@drreddys.com

Cardiovascular & Hematological Agents in Medicinal Chemistry

|July 17, 2007

Summary

Thrombosis, a dangerous condition of unwanted blood clot formation, is a leading cause of death. Recent advancements offer new antithrombotic drugs, including anticoagulants and antiplatelets, to combat these thromboembolic diseases.

Related Experiment Videos

Area of Science:

Cardiovascular Medicine
Hematology
Pharmacology

Background:

Thrombosis results from an imbalance in hemostasis, leading to intravascular thrombus formation.
This imbalance can cause severe conditions like stroke and heart attack, making thromboembolic diseases a major cause of mortality.
Significant progress in antithrombotic drug development has been made over the last decade.

Purpose of the Study:

To review important antithrombotic drugs launched in recent years.
To discuss novel pathways and targets in coagulation, fibrinolytic, and integrin systems.
To provide an overview of emerging therapeutic strategies for thrombotic disorders.

Main Methods:

Literature review of recent advancements in antithrombotic drug development.
Classification of antithrombotic drugs into anticoagulants, antiplatelets, and thrombolytics.
Discussion of novel therapeutic targets and pathways.

Main Results:

Antithrombotic drugs are broadly categorized into anticoagulants, antiplatelets, and thrombolytics.
Newer agents like clopidogrel, GP IIb/IIIa inhibitors, low molecular weight heparin, and direct thrombin inhibitors are now in clinical use.
Research is actively exploring novel pathways in coagulation, thrombolysis, fibrinolysis, and integrin systems.

Conclusions:

The development of novel antithrombotic agents has significantly advanced the treatment of thrombotic and vascular disorders.
Continued research into new targets promises further improvements in managing conditions like stroke and myocardial infarction.
Understanding the pathobiology of thrombosis is crucial for developing effective therapeutic interventions.